Physician profile
James Lee
NPI 1750358735
$13,951.94
in general payments reported to CMS, 2019-2025
42 companies · $2,769 in 2025
The $2,769 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $718 · 2021: $1,604 · 2022: $2,207 · 2023: $2,579 · 2024: $2,596 · 2025: $2,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,944.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,959.26 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,173.59 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $906.00 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $785.32 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $696.08 | 2019-2025 | Stelara, Remicade, Simponi |
| Madrigal Pharmaceuticals | $610.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $576.70 | 2019-2025 | |
| Ardelyx, INC. | $525.66 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $443.13 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $415.42 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $314.00 | 2024-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $261.72 | 2019-2023 | |
| Intercept Pharmaceuticals, INC. | $242.75 | 2019-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $219.73 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $213.57 | 2019-2024 | Rebyota |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.04 | 2023-2024 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $135.78 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $124.94 | 2019-2020 | |
| Amgen INC. | $123.91 | 2021-2024 | Tavneos |
| Lilly USA, LLC | $106.70 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $103.74 | 2019-2024 | Linzess |
| Braintree Laboratories, INC. | $86.14 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $75.69 | 2023 | Idacio |
| Redhill Biopharma INC. | $75.05 | 2020-2023 | Movantik, Aemcolo, Talicia |
| Shionogi INC | $71.04 | 2019 | |
| Celltrion USA INC. | $64.00 | 2024-2025 | Vegzelma, Zymfentra |
| Sanofi-Aventis U.S. LLC | $60.76 | 2025 | |
| Ucb, INC. | $45.28 | 2019 | |
| Allergan, INC. | $43.65 | 2019-2020 | |
| Shield Therapeutics INC | $42.90 | 2022 | |
| Intra-Sana Laboratories | $38.32 | 2021 | |
| Albireo Pharma, INC. | $36.78 | 2024 | Iqirvo |
| Shire North American Group INC | $34.52 | 2019 | |
| Daiichi Sankyo INC. | $31.71 | 2019 | |
| Vivus LLC | $29.81 | 2024-2025 | Qsymia, Pancreaze |
| Biocon Biologics INC | $26.24 | 2025 | Hulio |
| Alnylam Pharmaceuticals INC. | $24.21 | 2022 | |
| Erbe USA INC | $20.40 | 2019 | |
| Amag Pharmaceuticals, INC. | $20.32 | 2019 | |
| Cook Medical LLC | $18.42 | 2019 | |
| Exact Sciences Corporation | $16.55 | 2023 | Cologuard Collection Kit |
| Evoke Pharma, INC. | $16.07 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.